As­traZeneca says it is prun­ing staff at Med­Im­mune, its bi­o­log­ics R&D cen­ter

As­traZeneca’s big U.S. sub­sidiary Med­Im­mune, with 2200 em­ploy­ees, is prun­ing its work­force as it adds a greater em­pha­sis on its on­col­o­gy R&D work–but it’s not spec­i­fy­ing just many staffers are in­volved.

Here’s the state­ment:

In April, As­traZeneca an­nounced the sharp­en­ing of our fo­cus on our main ther­a­py ar­eas to pri­or­i­tize our pipeline and im­prove ef­fi­cien­cy and pro­duc­tiv­i­ty across the or­ga­ni­za­tion.  This will see the com­pa­ny al­lo­cate ad­di­tion­al in­vest­ment to core ar­eas, par­tic­u­lar­ly on­col­o­gy. This is a nat­ur­al pro­gres­sion of our strat­e­gy and re­flects in­creased pipeline pro­duc­tiv­i­ty, as well as the evolv­ing shape of the over­all com­pa­ny port­fo­lio with a grow­ing pro­por­tion of spe­cial­ty-care med­i­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER